The integrity of genomes is constantly threatened by problems encountered by the replication fork. BRCA1, BRCA2 and a subset of Fanconi anaemia proteins protect stalled replication forks from degradation by nucleases, through pathways that involve RAD51. The contribution and regulation of BRCA1 in replication fork protection, and how this role relates to its role in homologous recombination, is unclear. Here we show that BRCA1 in complex with BARD1, and not the canonical BRCA1-PALB2 interaction, is required for fork protection. BRCA1-BARD1 is regulated by a conformational change mediated by the phosphorylation-directed prolyl isomerase PIN1. PIN1 activity enhances BRCA1-BARD1 interaction with RAD51, thereby increasing the presence of RAD51 at stalled replication structures. We identify genetic variants of BRCA1-BARD1 in patients with cancer that exhibit poor protection of nascent strands but retain homologous recombination proficiency, thus defining domains of BRCA1-BARD1 that are required for fork protection and associated with cancer development. Together, these findings reveal a BRCA1-mediated pathway that governs replication fork protection.
1
. To prevent stalled forks collapsing into DNA double-strand breaks, a number of responses are elicited, which include the remodelling of forks and subsequent protection of nascent strands. Agents that cause replicative stress or that compromise the function of DNA polymerase α result in the reversing of a proportion of forks (reviewed in previous studies 2, 3 ). The regressed arm of nascent DNA in reversed forks resembles a single-ended DNA double-strand break, and breaks of this type are protected from excessive resection by RAD51. Several proteins contribute to RAD51-mediated fork protection, including BRCA1 and BRCA2, FANCA and FANCD2, RAD51 paralogues (such as RAD51C), BOD1L, SETD1A, WRNIP and ABRO1 2 . One emerging theme is that stabilization of RAD51 within the nucleoprotein filament is critical for the protection of stalled forks [4] [5] [6] . RAD51 mutants that show increased dissociation from DNA are compromised in their ability to prevent fork degradation [6] [7] [8] , whereas factors that stabilize the interaction between RAD51 and single-stranded DNA (such as BOD1L) promote fork protection 9 . Other factors (for example, RADX) compete with or dissociate RAD51, and depletion of these factors rescues fork protection in cells that are deficient in BRCA1 or BRCA2 10, 11 . Failure to protect stalled forks is associated with genomic instability. Furthermore, restoration of replication fork protection in BRCA1-or BRCA2-deficient cells is linked to resistance to chemotherapy in some cell types and contexts [12] [13] [14] . Thus, a better mechanistic understanding of the role of BRCA1 in fork protection is needed to inform the care and treatment of patients with cancer.
BRCA1 is found at ongoing and stalled replication forks 15, 16 and, similar to BRCA2, contributes to RAD51-mediated protection of stalled forks from MRE11-dependent degradation 17 . However, how BRCA1 contributes to fork protection is unclear. Here we show that BRCA1 promotes the protection of nascent DNA at stalled replication forks independently of the canonical BRCA1-PALB2 interaction. We find that an enhanced, direct interaction between the BRCA1-BARD1 complex and RAD51 is associated with protection of the nascent strand, and that interaction and fork protection depend on the activity of the phosphorylation-directed prolyl isomerase, PIN1. We identify regions of the BRCA1 and BARD1 proteins that are required for fork protection, and show that genetic variants of BRCA1 and BARD1 that are associated with familial and sporadic cancer inhibit fork protection.
Phosphorylation of BRCA1 S114 promotes fork protection
During the repair of DNA double-strand breaks by homologous recombination, BRCA1-BARD1 regulates the localization and loading of RAD51 at break sites through PALB2-BRCA2 [18] [19] [20] , but it is unclear whether BRCA1 acts through this pathway in replication fork protection. We examined nascent DNA sequentially labelled with the thymidine analogues 5-chloro-2′-deoxyuridine (CldU) and 5-iodo-2′-deoxyuridine (IdU) at forks stalled by hydroxyurea (5 mM, 3 h) 5, 17 in human cells in which the expression of BRCA1 or PALB2 was knocked down by transfection with short interfering RNA (siRNA). Both BRCA1-and PALB2-depleted cells showed a decreased IdU:CldU ratio, which is consistent with defective fork protection (Extended Data Fig. 1a-c) . Variants of BRCA1 and PALB2 that have mutations in the coiled-coil domains (BRCA1(M1411T) or PALB2 with an N-terminal deletion, PALB2(ΔNT)) are unable to directly interact with one another, fail to support the repair of DNA by homologous recombination and exhibit increased sensitivity to the inter-strand cross-linker cisplatin 19, . Although cells complemented with BRCA1(M1411T) or PALB2(ΔNT) showed increased fork stalling and defects in restarting of the replication fork after treatment with hydroxyurea, the mutants were still proficient in protection of stalled replication forks (Extended Data Fig. 1j-o ). These results demonstrate that fork protection is independent of the canonical BRCA1-PALB2 interaction.
Article reSeArcH BRCA1 and BARD1 interact directly with RAD51 21, 22 and mutation of the BARD1 residues Phe133, Asp135 and Ala136 (F133A/D135A/ A136E; hereafter termed AAE) disrupts the BARD1-RAD51 interaction, causing reduced resistance to mitomycin C 21 , olaparib and hydroxyurea (Extended Data Fig. 2a, b) . Complementation of cells with BARD1(AAE) did not support protection of nascent strands, in contrast to cells that were complemented with wild-type BARD1 or with BARD1(R99E), a BARD1 mutant that is deficient in ubiquitin ligase activity 23 (Extended Data Fig. 2c-f) . Thus, protection of stalled replication forks requires the region of BARD1 that contains the RAD51-binding site, but does not require ligase activity of the BRCA1-BARD1 heterodimer.
BRCA1 and BARD1 are phosphorylated at residues that are potentially located close to the site of interaction between BARD1 and RAD51: Ser148 of BARD1 24 and Ser114 of BRCA1
25
. Substitution of these sites to alanine residues (BRCA1(S114A) and BARD1(S148A)) caused a reduction of IdU:CldU ratios and CldU tract lengths after treatment with hydroxyurea-consistent with defective fork protection (Fig. 1a, b, . By contrast, mutation of these serine residues to aspartic acid-which mimics phosphorylated serine-supported fork protection in cells that were complemented with BRCA1(S114D), but not in those complemented with BARD1(S148D) (Fig. 1a, b, Extended Data Fig. 3d, e) , which suggests that phosphorylation of BRCA1 has a role in fork protection. Immunoblotting for BARD1(S148D) revealed the presence of a smaller BARD1 band (Extended Data Fig. 3e ), which indicates cleavage of this mutant.
BRCA1(S114A) and wild-type BRCA1 showed similar levels of recruitment to active replication sites, comparable interactions with BARD1, and restoration of ongoing forks and fork restart after three hours of treatment with 5 mM hydroxyurea (Extended Data Fig. 3f-i) , which suggests that the Ser114 site is not important to these aspects of replication stress. Treatment of BRCA1-or BRCA2-deficient cells with mirin-an inhibitor of MRE11 3′-5′ exonuclease activity-restored fork protection 17 and, likewise, mirin treatment restored long CldU tract lengths in BRCA1(S114A)-complemented cells (Extended Data Fig. 3j, k) , which implicates the Ser114 site in the protection of nascent DNA from nuclease activity.
We generated an antibody against BRCA1 peptide phosphorylated at Ser114 (BRCA1(pS114)), which detected immunoprecipitated wild-type BRCA1 but not BRCA1(S114A) (Fig. 1c) . Notably, the phosphorylated Ser114 residue is found within an Ser-Pro motif that is a minimal consensus sequence for the phosphorylation-targeted peptidyl-prolyl isomerase (PPIase) PIN1, and BRCA1 and BARD1 have previously been enriched from lysates using recombinant PIN1 26 . We confirmed this interaction through immunoprecipitation of the BRCA1-BARD1-PIN1 complex (Fig. 1d) . Next, we created a recombinant protein, GST-WW, in which the PIN1 WW domain (the binding domain for phosphorylated serine or threonine before a proline residue) was fused to glutathione S-transferase, and found that GST-WW, but not a GST-WW(W34A) mutant that is unable to bind the motif 27 , could purify wild-type BRCA1 and BRCA1(S114D). By contrast, neither GST-WW nor GST-WW(W43A) purified BRCA1(S114A) (Fig. 1e, Extended Data Fig. 4a-c) . Furthermore, the interaction between exogenous or endogenous BRCA1 and recombinant GST-WW was increased after treatment with hydroxyurea, and lost following treatment of the cell lysate with phosphatase ( Fig. 1f , Extended Data Fig. 4d, e) . Although wild-type BARD1 was also purified by GST-WW, this interaction was not lost when RAD51 was mutated at the proximal phosphorylation site Ser148 (BARD1(S148A) (Extended Data Fig. 4f ). Together, these data suggest that BRCA1 phosphorylation at Ser114 is upregulated in response to hydroxyurea, and that this enables the PIN1 GST-WW construct to purify BRCA1.
To identify the kinase(s) that are responsible for phosphorylating BRCA1 at Ser114, we performed a kinase inhibitor screen that targeted members of the proline-directed kinase superfamily. Treatment with an inhibitor of CDK1 and CDK2 (roscovitine), but not with inhibitors of JNK1 and JNK2 (SP600125), DYRK proteins (INDY), MEK1 and MEK2 (U0126) or GSK (inhibitor IX), reduced the ability of GST-WW to enrich BRCA1 from cell lysates (Extended Data Fig. 4g, h ). Consistent with this, the BRCA1 Ser114 site lies within a loose consensus site for CDK1 and CDK2 (SPXXXK (in which X denotes any amino acid)). Treatment of cells with the CDK1 inhibitor RO-3306 or with siRNA against CDK1 reduced the ability of the antibody that we generated against BRCA1(pS114) to recognise, or the GST-WW domain to purify, BRCA1 from cell lysates (Fig. 1g, Extended Data  Fig. 4i) . Similarly, incubation of recombinant BRCA1 1-300 -BARD1 with constructs that were engineered to express either CDK1 and cyclin A2, or CDK2 and cyclin A, resulted in phosphorylation of wild-type BRCA1 at Ser114; by contrast, recombinant constructs that expressed CDK9 and cyclin K did not elicit BRCA1 phosphorylation 28 (Extended Data Fig. 4j-l) . These data suggest that CDK1 and CDK2 CldU ratios from U20S cells in which BRCA1 expression was knocked down by siRNA transfection, cells were complemented with Flag-eGFP-tagged BRCA1 variants and treated with hydroxyurea (5 mM, 3 h). n = 205 fibres from 2 biological replicates; bars depict median ± 95% confidence interval (CI). NTC, no template control; WT, wild type. b, Representative blot (n = 3). c, Detection of BRCA1(pS114) (using rabbit polyclonal antibody) in immunoprecipitation (IP) from HEK293 cells that express Flag-eGFP-tagged wild-type BRCA1 or Flag-eGFP-tagged BRCA1(S114A). Representative blot (n = 3). d, Representative immunoprecipitation from U20S cells that express RFP-Flag-tagged BARD1. n = 3. e, Representative image of GST-WW pull-down assay from U20S cells that express Flag-eGFP-tagged wild-type BRCA1 or Flag-eGFP-tagged BRCA1(S114A). GST-WW(W34A) was used as a negative control. n = 4; data are mean ± s.e.m. f, Quantification of enrichment in GST-WW pull-downs from HEK293 cell lysates that express Flag-eGFP-tagged wild-type BRCA, with or without hydroxyurea (HU) treatment (3 mM, 6 h). n = 4; data are mean ± s.e.m. g, BRCA1(pS114) was measured after immunoprecipitation of FlageGFP-tagged BRCA1 from HEK293 cells treated with 5 μM RO-3306 (an inhibitor of CDK1 and CDK2). Representative blot (n = 3). h, i, Representative images (h) and quantification (i) of PLA between BRCA1(pS114) and EdU-biotin in U20S cells at ongoing (−HU) or stalled (+HU) forks that were pulse-labelled with EdU. Data in i include data from cells depleted for BRCA1 (siBRCA1) or treated with CIP or roscovitine (Ros; 25 μM). Scale bars, 10 μm. n = 150 cells from 3 biological replicates; bars depict median ± 95% CI. A two-sided unpaired t-test was used to calculate all P values. For gel source data in this figure and throughout, see Supplementary Fig. 1 .
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are the dominant kinases responsible for phosphorylation of Ser114 in BRCA1. Given the increase in BRCA1(pS114) after treatment of cells with hydroxyurea, we next examined whether BRCA1(pS114) locates to sites of stalled replication forks. Using a proximity ligation assay (PLA), we assessed the potential proximity between 5-ethynyl-2′deoxyuridine (EdU) (incorporated at ongoing forks or at forks stalled by hydroxyurea treatment) and our phosphorylation-specific BRCA1(pS114) antibody. We observed a BRCA1-dependent PLA signal in cells that had been treated with hydroxyurea, and this signal was partially reduced when cells were treated with calf intestinal phosphatase (CIP) or roscovitine (Fig. 1h, i) . Together, these data suggest that BRCA1(pS114) is localized to stalled replication forks.
PIN1 regulates BRCA1-BARD1
PIN1 has previously been found to be enriched in isolated proteins on nascent DNA (iPOND) from cells treated with hydroxyurea 10 .
We tested whether fork protection requires PIN1, and found that depletion of PIN1 or inhibition with juglone led to shortened CldU tracts and reduced IdU:CldU ratios after hydroxyurea treatment-consistent with a defect in fork protection (Fig. 2a, b , Extended Data Fig. 5a ). Co-depletion of PIN1 with BRCA1 or BARD1 did not reduce nascent strand lengths further (Fig. 2a, b, Extended Data Fig. 5b, c) . PIN1 depletion did not have a discernible effect on the levels of BRCA1 or BARD1 proteins (Fig. 2b, . In folded proteins, peptide bonds that precede residues other than proline (non-prolyl bonds) overwhelmingly favour the trans form, and cis bonds are rare 29 . Owing to the physical constraints of prolinewhich has a unique side chain that forms a five-membered ringpeptide bonds that precede proline (prolyl bonds) may adopt the cis conformation
30
. PIN1 is the only phosphorylation-targeted PPIase that CldU ratios from U20S cells in which BRCA1 and/or PIN1 expression was knocked down by siRNA transfection and cells were treated with hydroxyurea (5 mM, 3 h). n = 300 fibres from 3 biological replicates; bars depict median ± 95% CI. b, Representative blot (n = 3). c, Schematic to illustrate cis-trans isomerization around the Ser114 phosphorylation site in BRCA1. d, e, IdU:CldU ratios from U20S cells in which BRCA1 expression was knocked down by siRNA transfection, cells were complemented with Flag-eGFP-tagged BRCA1 variants and treated with hydroxyurea (5 mM, 3 h). n = 320 fibres from 3 biological replicates; bars depict median ± 95% CI. e, Representative blot (n = 3). f, g, As for d, e but in cells in which expression of both BRCA1 and PIN1 was knocked down by siRNA transfection. n = 195 fibres from 2 biological replicates; bars depict median ± 95% CI. g, Representative blot (n = 2). A two-sided unpaired t-test was used to calculate all P values. NS, not significant.
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---- His-tagged BARD1 26-142 were incubated with full-length GST-PIN1 to induce isomerization or with catalytically inactive GST-PIN1(C113S) as a control. His-tagged phosphorylated BRCA1-BARD1 complexes were incubated with recombinant active RAD51, and binding of RAD51 was assessed by His purification. Representative blot (n = 3). b, Recombinant His-tagged wild-type BRCA1 1-500 or BRCA1 1-500 (P115A) and BARD1 were incubated with recombinant active RAD51 and His purification was performed to assess formation of the BRCA1-BARD1-RAD51 complex. Representative blot (n = 5). Article reSeArcH specifically recognizes phosphorylated Ser/Thr-Pro motifs 31 before catalysing a conformational change of the peptidyl-prolyl bond from the cis to the trans form [32] [33] [34] [35] . To examine the role of the trans isomer, the target proline residue can be substituted with another amino acid to increase the probability of the trans form 36, 37 . We mutated BRCA1 Pro115 to an alanine or a cysteine residue and found that fork protection was maintained in both mutants (Fig. 2d , e, Extended Data Fig. 5f, g ), which suggests that proline mutation or trans isomerization at this position is not deleterious. Notably, introducing P115A or P115C mutations concurrently with the S114A mutation in BRCA1-depleted cells restored IdU:CldU ratios to control levels (Fig. 2d , e, Extended Data Fig. 5f, g ), showing that mutation of Pro115 can overcome the requirement for a serine residue at position 114. In cells that were co-depleted for BRCA1 and PIN1, we similarly found that expression of BRCA1(P115A) or BRCA1(S114A/P115A) resulted in IdU:CldU ratios that were close to 1, in contrast with cells that expressed wildtype BRCA1 (ratios of 0.5) (Fig. 2f, g ). Together, these data show that the requirement for PIN1 in fork protection can largely be overcome by the mutation of Pro115 in BRCA1.
BRCA1 isomerization aids the binding of RAD51
Both BRCA1 and BARD1 have regions located proximally to RING domains that are important in fork protection: BRCA1 contains the 114-Ser-Pro-115 regulatory region, and BARD1 contains a region that is required for the binding of RAD51. As these regions may potentially be located in close physical proximity to one another, we next asked whether PIN1 influences the interaction between BRCA1-BARD1 and RAD51. Using recombinant proteins, we first incubated heterodimers of His-tagged wild-type BRCA1 1-500 -BARD1 27-327 and the phosphomimetic mutant BRCA1 1-500 (S114D)-BARD1 27-327 with full-length GST-PIN1, before further incubation with purified recombinant RAD51. We then used pull-down of histidine to examine the interaction between BRCA1-BARD1 and RAD51. Only the heterodimer that included the S114D phosphomimetic mutation in BRCA1 and had been incubated with GST-PIN1 was able to bind RAD51 (Extended Data Fig. 6a, b ). To test this further, we next used a recombinant construct that expressed CDK1 and cyclin A2 to phosphorylate BRCA1 1-300 -BARD1 26-142 (Extended Data Fig. 4j-l) , and incubated this with either full-length wild-type GST-PIN1 or GST-PIN1(C113S) (Fig. 3a , Extended Data Fig. 6b ). The C113S mutation inhibits PIN1-mediated isomerization 38 but does not prevent the interaction of PIN1 with its target proteins 39 . Only phosphorylated BRCA1 1-300 -BARD1 26-142 that had been incubated with active wild-type GST-PIN1 was able to bind RAD51 (Fig. 3a) . These data confirm the requirement for BRCA1 phosphorylation and demonstrate that PIN1 activity is necessary to enhance the binding of RAD51 to the BRCA1-BARD1 heterodimer. Finally, we generated recombinant purified wild-type BRCA1 1-500 -BARD1 27-327 and BRCA1 1-500 (P115A)-BARD1 27-327 (Extended Data Fig. 6c ) and incubated these with RAD51 in the absence of PIN1. We found that the BRCA1-BARD1 heterodimer with the Pro115 mutation in BRCA1 interacted more strongly with RAD51 than the heterodimer with wild-type BRCA1 (Fig. 3b) . These data are consistent with the finding that PIN1 activity is needed to increase RAD51 binding, and also suggest that the presence of PIN1 does not directly contribute to the interaction between RAD51 and the BRCA1-BARD1 heterodimer.
As BRCA1 also contains a RAD51-binding region (amino acids 708-1064), the effect of regulation around BRCA1 residue 115 may differ in the context of the full-length proteins. Using full-length BRCA1-BARD1 purified from insect (Sf9) cells, we found that both wild-type and BRCA1(P115A)-BARD1 interacted with RAD51, but the interaction was stronger for the heterodimers that contained BRCA1(P115A) (Extended Data Fig. 6d , e). Moreover, BRCA1(P115A)-BARD1 that was immunoprecipitated from mammalian cells showed a similar level of enrichment for RAD51 (approximately 1.5-fold that of wild type) (Extended Data Fig. 6f, g ). We subjected full-length recombinant wild-type BRCA1-BARD1 to limited proteolysis with trypsin and found that the rate of digestion of BRCA1 was virtually unchanged by inclusion of the P115A mutation. Notably, however, the rate of digestion of BARD1 was increased by inclusion of BRCA1(P115A) in the heterodimer as compared to wildtype BRCA1 (Fig. 3c, d , Extended Data Fig. 6h ), which indicates that the presence of BRCA1(P115A) increases the accessibility of BARD1 to degradation. We next assessed by PLA 40 whether mutations of BRCA1 at Ser114 and Pro115 influence the presence of RAD51 at nascent DNA after treatment with hydroxyurea 4, 5 . Cells that were complemented with BRCA1(S114A) were unable to restore wild-type levels of EdU-RAD51 PLA foci, in contrast to cells that were complemented with BRCA1(S114A/P115A) (Fig. 3e , Extended Data Fig. 6i ). These data suggest that the P115A mutation in BRCA1 overcomes the requirement for a functional phosphorylation site or serine at Ser114 to promote the accumulation of RAD51 at nascent DNA. Likewise, in cells co-depleted for BRCA1 and PIN1, wild-type levels of EdU-RAD51 PLA foci were restored by complementation of BRCA1(S114A/P115A) but not BRCA1(S114A) (Fig. 3f) . Thus, the contribution of PIN1 to RAD51 recruitment at stalled forks in cells can be overcome by expression of BRCA1(P115A).
Isomerization promotes genomic stability
Previous work has shown that Brca1-deficient mouse B cells (in which fork protection is enabled but homologous recombination deficiency is retained) exhibit reduced chromosomal aberrations following treatment with PARP inhibitors or cisplatin, and show resistance to hydroxyurea 12 . This suggests that the loss of fork-protection capability alone (that is, independently of any deficiency in homologous recombination) could be associated with altered responses to therapeutic agents. We found that human U20S cells that were complemented with BRCA1(S114A) were resistant to the PARP inhibitors olaparib, veliparib and 4AN and formed RAD51 foci after treatment with olaparib, but were sensitive to 16-h treatment with agents that induce replication stress (hydroxyurea and aphidicolin) (Fig. 4a , b, Extended Data Fig. 7a-g ). Because prolonged treatment with hydroxyurea causes fork collapse and double-strand breaks 41 , we also assessed colony survival in response to conditions that promote fork stalling but not collapse (3-h treatment with 5 mM hydroxyurea) 41, 42 . Even in asynchronous cells that underwent short-term (3-h) hydroxyurea treatment, cells that were complemented with BRCA1(S114A) showed reduced colony formation compared to those complemented with wild-type BRCA1 (Fig. 4b, c) . Moreover, inclusion of the P115A mutation on the S114A background was sufficient to rescue the S114A-associated defect in survival that was observed in response to both 3-h and 16-h treatment with hydroxyurea ( Fig. 4a-c) .
These data led us to investigate chromosome stability. Depletion of BRCA1 increased both the average number of chromosome breaks per metaphase and the percentage of metaphases with radial chromosomes (Fig. 4d-f) . Notably, complementation with BRCA1(S114A) restored the percentage of radial chromosomes-but not the number of chromosome breaks-to control and wild-type BRCA1 levels, and complementation with BRCA1(S114A/P115A) restored both phenotypes to control levels ( Fig. 4d-f ). These data suggest that the 114-Ser-Pro-115 region of BRCA1 is involved in the protection of nascent DNA and the prevention of chromosome breakages, and that it confers resistance to hydroxyurea.
Constitutive BRCA1(P115A) is genotoxic
We next questioned the necessity for such a complex mechanism of BRCA1-BARD1 regulation and whether the constitutive presence of a heterodimer that is primed for increased interaction with RAD51 and increased fork protection is deleterious. We constitutively expressed wild-type BRCA1 and BRCA1(P115A) in cells over several days. Cells were sampled at four-day intervals and assessed for BRCA1 expression, γH2AX foci (as a marker of DNA damage) and chromosome integrity in metaphase spreads ( Fig. 5a-d, Extended Data Fig. 7h ). Cells that expressed BRCA1(P115A) showed a significant increase in γH2AX staining and in the number of breaks per metaphase, compared with matched cells that expressed wild-type BRCA1 (Fig. 5a-d , Extended Data Fig. 7h ). Therefore, long-term exposure to BRCA1(P115A) promotes an increased rate of accumulation of DNA damage.
Fork protection in patient variants
Somatic and germline genetic variants that are associated with cancer have been found within or close to the 114-Ser-Pro-115 phosphorylation and isomerization site in BRCA1 and the RAD51-binding region in BARD1 [43] [44] [45] (https://research.nhgri.nih.gov/bic/). To assess whether replication fork protection is affected in these genetic variants, we generated point mutations that correspond to missense variants with a high Grantham difference and low variance (Fig. 6a, b) . The BRCA1 variants S114P, R133C, Y179C, S184C and S256Y, but not Y101N, and the BARD1 variants K144N and F147C, but not D135Y, showed reduced IdU:CldU ratios compared with controls, consistent with a defect in fork protection (Fig. 6c-f) . Moreover, all mutants that exhibited defective fork protection also showed increased sensitivity to hydroxyurea, whereas those that were proficient in fork protection did not ( Fig. 6g-i) .
The BRCA1(S114A) mutation supports several aspects of BRCA1 function: it prevents the formation of 'quadriradial' chromosomes (which are thought to result from faulty non-homologous end joining in cells that are deficient in the capacity for homologousrecombination-based repair) 46 ; allows the formation of RAD51 foci; enables resistance to PARP inhibitors; and promotes the restart of replication ( Fig. 4d-f, Extended Data Figs. 3i, 7b-g ). These features suggest that the mutation does not have a notable role in reducing homologousrecombination-repair proficiency. To assess whether patient variants that are located close to the 114-Ser-Pro-115 region of BRCA1 and the RAD51 interaction site of BARD1 show features of a defect in Article reSeArcH recombination, we examined complemented S-phase cells for RAD51 foci after irradiation, and for survival following treatment with cisplatin and both short-term (2-h) and continuous treatment with olaparib. Where possible, cells that expressed patient variants were also assessed for repair of an integrated homologous recombination substrate following the enzymatic generation of a DNA double-strand break (Extended Data Figs. 8, 9 and summarized in Extended Data Fig. 10a ). Of the BRCA1 variants that showed poor fork protection and hydroxyurea sensitivity, BRCA1(S114P) and BRCA1(R133C) were not sensitive to cisplatin or to short or continuous treatment with olaparib, and on exposure to ionizing radiation they showed levels of RAD51 foci that approached wild-type levels (Extended Data Fig. 8a-e) . Of the BARD1 variants that showed poor fork protection and increased hydroxyurea sensitivity, BARD1(K144N) and BARD1(F147C) were resistant to olaparib treatment, had levels of RAD51 foci that were close to wildtype levels and were resistant to all but the highest concentrations of cisplatin. In addition, when BARD1 patient variants were expressed in U20S DR-GFP reporter cells in which BARD1 was depleted, homologous recombination was restored to wild-type levels for all variants of BARD1 (Extended Data Fig. 9a-f ).
Discussion
Our data reveal a direct function for BRCA1 in fork protection that is separate from the canonical BRCA1-PALB2 interaction. Instead, we propose a model of regulation that is based on BRCA1-BARD1-RAD51, and we identify post-translational modifications of BRCA1 that are upregulated by hydroxyurea treatment and required for fork protection. Our findings support a model in which a conformational change in BRCA1, mediated by CDK1 or CDK2 and PIN1, results in an improved interface between BRCA1-BARD1 and RAD51 (Extended Data Fig. 10b ). Although PIN1 activity is capable of disrupting dimers and aggregates and driving interactions that are specific for cis or trans conformations 47, 48 , the mechanism that we describe here-in which isomerization on one partner of a heterodimer promotes improved protein-protein interactions that are mediated by the other partnerappears unique. The cancer-associated mutations that we identify in BRCA1-BARD1 extend the regions of both proteins that are known to be involved in fork protection. We also find that cells that express mutant forms of BRCA1 or BARD1 that are specifically deleterious to fork protection are resistant to olaparib and cisplatin. This is consistent with previous findings in mice: mouse cells with mutations in the BRCT domain of BARD1 are deficient in protection of the nascent strands, owing to poor recruitment of the heterodimer to stalled forks, and these cells show similar resistance to olaparib 49 . Our findings build on the view that greater RAD51 interactions with homologousrecombination-related proteins at stalled replication forks promote fork protection. However, further investigation is required to explain how the increased interaction of RAD51 with BRCA1-BARD1 specifically contributes to the function of RAD51 in fork protection. Our current ability to analyse fork protection remains crude; the measurements are based on observations that take place after prolonged fork stalling and are therefore unlikely to be directly relevant physiologically. A greater understanding of the mechanisms of fork protection will thus be required to accurately assess the relationship of fork protection with therapeutic resistance or sensitivity.
Mice with Bard1 mutations that confer a defect in fork protection are not tumour-prone 49 , and restoration of fork protection in a Brca2 knockout model of cancer accelerates rather than slows the formation of tumours 50 . Moreover, homologous recombination-and not the protection of stalled forks-is associated with promoting cell viability in human mammary cells 14 . The balance of current evidence does not therefore favour fork protection as a mechanism of tumour suppression. Nevertheless, here we have shown that seven patient-derived variants of BRCA1-BARD1 impair fork protection, and that four of these appear to have little effect on DNA repair by homologous recombination. These data provide a framework to address whether and how BRCA1-mediated fork protection relates to cancer development.
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Methods
Data reporting.
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Site-directed mutagenesis. Specific primers were designed for mutagenesis (Supplementary Table 1 ) and mutagenesis was performed by PCR using PfU (Promega). All mutagenesis was confirmed by Sanger Sequencing (Source Bioscience). Tissue culture. Parental Flp-In HeLa, U20S and HEK293 cells were obtained from cell stocks in the J.R.M. laboratory and grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin. Cells were cultured in Corning T75 flasks, on 10-cm 2 plates, and kept at 5% CO 2 and 37 °C. Once cells reached 70-80% confluency they were passaged. Cells were tested for mycoplasma by Hoescht staining. Cell lines have not been authenticated. Generation of stable, inducible cell lines. Stable cell lines were generated from Flp-In HeLa, U20S and HEK293 cells that were co-transfected with the cDNA of the gene of interest in the pcDNA5/FRT/TO vector, and with the Flp recombinase cDNA in the pOG44 vector. Control transfections were carried out without the pOG44 recombinase. Two days after transfection, cells were selected with 100 μg ml −1 hygromycin, the culture medium was replaced every two to three days and cells were selected for approximately two weeks. After selection, cells were expanded and tested for expression of Flag-eGFP-tagged BRCA1, RFPFlag-tagged BARD1 or Flag-tagged PALB2. Cells were treated with 2 μg ml −1 doxycycline for 24, 48 and 72 h and expression levels were analysed by western blotting. Plasmid and siRNA transfection. FuGENE 6 (Roche) was used as a reagent to transfect cells with DNA plasmids. The ratio used was 4:1 FuGENE (μl):DNA (μg), following the manufacturer's guidelines. siRNA transfections were carried out using the transfection reagent Dharmafect1 (Dharmacon) following the manufacturer's instructions. For a full list of siRNA sequences see Supplementary Table 2 . Colony survival assays. Flp-In U20S or HeLa cells were plated in 24-well plates at 4 × 10 4 cells per ml and treated according to the experiment performed. Cells were trypsinized in 100 μl 1× trypsin and resuspended in 900 μl PBS. Cells were plated out at limiting dilutions and incubated for a further 10-14 days at 37 °C at 5% CO 2 . Once colonies had grown they were stained with 0.5% crystal violet in 50% methanol and counted. For a full list of DNA-damaging agents and inhibitors, see Supplementary Table 3 .
Pull-down assays for PIN1 WW constructs (GST-WW and GST-W34A).
Cells were washed with 10 ml ice-cold PBS before being lysed in 5 ml TG lysis buffer (40 mM Tris HCl pH 8, 274 mM NaCl, 2 mM EGTA, 3 mM MgCl 2 , 2% Triton X-100, 20% glycerol) with the addition of cOmplete protease inhibitor cocktail (Roche) and PhosSTOP (Roche) tablets. The lysed cells were transferred into 1.5-ml Eppendorf tubes, incubated on ice for 20 min and sonicated twice at 20% intensity for 10 s. Samples were spun at 13,000 r.p.m. at 4 °C for 10 min and the supernatant was kept. A 50-μl sample of the supernatant was mixed with 20 μl 4× SDS loading buffer and boiled at 95 °C for 5 min. Then, 800 μl of the cell supernatant was incubated with equal concentrations of GST-WW and GST-W34A beads for 2 h at 4 °C. The GST pull-downs were washed 3 times in TG lysis buffer before adding 60 μl 4× SDS loading buffer directly to the beads. Samples were boiled at 95 °C for 5 min and then 40 μl was loaded onto an SDS-PAGE gel and analysed by western blotting. Flag immunoprecipitation. Stable U20S or HEK293 cells were plated in a 10-cm 2 plate and treated with doxycycline for 48 h to express inducible Flag-eGFP-tagged BRCA1 or RFP-Flag-tagged BARD1, or HEK293 cells were transiently transfected with 4 μg pcDNA5/FRT/TO-Flag-eGFP-BRCA1 and/or pcDNA5/FRT/TO-RFPFlag-BARD1 for 48-72 h. Cells were washed with 10 ml ice-cold PBS before being scraped into ice-cold nuclear lysis buffer (10 mM HEPES pH 7.6, 200 mM NaCl, 1.5 mM MgCl 2 , 10% glycerol, 0.2 mM EDTA, 1% Triton) with addition of cOmplete protease inhibitor cocktail (Roche) and PhosSTOP (Roche) tablets, 1 U ml
DNase1 (Thermo Fisher Scientific) and 20 μM MG132 for every 10 ml. The lysed cells were then transferred into 1.5-ml Eppendorf tubes and incubated on ice for 30 min. Samples were spun at 13,000 r.p.m. at 4 °C for 10 min and the supernatant was kept; the pellet was discarded. Then, 50 μl of the supernatant was mixed with 20 μl 4× SDS loading buffer and boiled at 95 °C for 5 min. For every immunoprecipitation, 10 μl Flag agarose beads were first washed out of storage buffer by washing three times in 1 ml PBS and centrifuging at 3,000 r.p.m. between each wash. A total of 90 μl PBS was added for every 10 μl agarose beads. Once the beads were resuspended in PBS, 100 μl were transferred into an Eppendorf tube with 500 μl of supernatant and 500 μl of PBS. The Eppendorf tubes were rotated for 2 h at 4 °C. Samples were centrifuged at 3,000 r.p.m. for 1 min and the beads were left to settle. The supernatant was then removed before the washing three times with PBS containing 0.02%Tween. The wash buffer was completely removed before adding 60 μl 2× SDS loading buffer. This was boiled at 95 °C for 5 min and then 30 μl was loaded onto an SDS-PAGE gel and analysed by western blotting.
Western blotting. For a full list of antibodies, see Supplementary Table 4 . Samples were run on SDS-PAGE protein gels and transferred to an Immobilon-P PVDF membrane. Following transfer, membranes were blocked in 5% Marvel milk in PBS containing 0.1% Tween (PBStw), or in 5% BSA with PBStw, for a minimum of 1 h before incubation with primary antibody at 4 °C for 16 h. Blots were washed 3 times (10 min each) in PBStw and then transferred into secondary horseradish peroxidase (HRP)-conjugated antibodies in 5% Marvel milk for a minimum of 1 h. Blots were again washed 3 times (10 min each) in PBStw before probing with 1:1 EZ-ECL mix (Biological Industries). Blots were exposed to X-ray film (Wolf Labs) and developed using the Xograph Compact X4 developer. Densitometry calculations were performed using ImageJ 53 . Uncropped gel images for western blots are available in Supplementary Fig. 1 . Generation of the BRCA1(pS114) antibody. Custom mouse monoclonal (3C10G8) and rabbit polyclonal antibodies were raised against BRCA1(pS114) by Genscript using the following peptide: CFAKKENNpSPEHLKD (in which p indicates a phosphorylated residue). These antibodies are available on request to the corresponding authors subject to completion of a standard MTA. Labelling and spreading of fibres. Cells were seeded in 6-cm 2 plates at a density of 20 × 10 4 cells per well and treated with the thymidine analogues CldU and IdU. To monitor stability of nascent DNA, cells were incubated at 37 °C with CldU for 20 min at a final concentration of 25 μM, followed by incubation with IdU (250 μM) for 20 min and then with 5 mM hydroxyurea for 3 h. To monitor CldU fibre lengths, cells were incubated at 37 °C with CldU for 20 min at a final concentration of 25 μM and then with 5 mM hydroxyurea for 3 h. To monitor replication fork restart, cells were incubated at 37 °C with CldU for 20 min at a final concentration of 25 μM and then with 5 mM hydroxyurea for 3 h. The hydroxyurea was then washed out with 3× PBS washes and cells were incubated for a further 40 min in medium containing 250 μM IdU at 37 °C.
After incubation with thymidine analogues, cells were washed twice with ice-cold PBS for 5 min with rotation then trypsinized, resuspended in 1 ml PBS and counted. The optimal concentration is 50 × 10 4 cells ml −1 , and thus cells were adjusted to this concentration. Exactly 2 μl of the cell sample was placed on Snowcoat microscope slides and allowed to slightly dry for 7 min. Then 7 μl of spreading buffer (200 mM Tris pH 7.4, 50 mM EDTA, 0.5% SDS) was mixed with the sample and incubated for 2 min to lyse the cells. To spread the sample down the slide, slides were gradually tilted and once the sample had reached the bottom of the slide, they were allowed to dry for 2 min. Finally, slides were fixed in a 3:1 ratio of methanol:acetic acid for 10 min before being left to air dry for 5-10 min. Dried slides were stored at 4 °C until staining. Fibre immunostaining. After fibre spreading, slides were washed twice for 5 min with 1 ml H 2 O and rinsed with 2.5 M HCl before denaturing the DNA with 2.5 M HCl for 1 h 15 min. Slides were then rinsed twice with PBS and washed for 5 min in blocking solution (PBS, 1% BSA, 0.1% Tween 20). Slides were incubated for 1 h in blocking solution. After blocking, each slide was incubated with 115 μl of primary antibodies: rat anti-BrdU (1:2,000; AbD Serotec or Abcam) to detect CldU, and mouse anti-BrdU (1:750; Becton Dickinson) to detect IdU. Slides were covered with large coverslips and incubated with the antibodies for 1 h. After incubation with the primary antibody, slides were rinsed three times with PBS and then incubated for 1 min, 5 min and 30 min, with blocking solution. After rinsing and washing, slides were incubated with 115 μl of secondary antibodies (anti-rat Alexa Fluor 555 and anti-mouse Alexa Fluor 488; 1:500) in blocking solution, and covered with a large coverslip for 2 h. Slides were rinsed three times with PBS and incubated with blocking solution for 1 min, 5 min and 30 min. After again rinsing twice with PBS, Immunomount mounting medium was added to the slide and a large coverslip was placed over and left to dry. Coverslips were then stored at −20 °C for microscopy analysis. Slides were kept protected from light during this process.
Following imaging using a Leica DM6000B fluorescence microscope, CldU and IdU fibre lengths were measured for ongoing forks that contained both labels, using ImageJ
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.The ratio of IdU:CldU was determined for each ongoing fork for a minimum of 100 fibres per experiment and each experiment was repeated 3 times.
Fork restart was measured as the percentage of fibres with incorporation of both labels (CldU and IdU). Stalled forks were fibres that only incorporated the first label (CldU). Percentage was calculated relative to the total number of fibres counted. Immunofluorescence staining. U20S wild-type or BRCA1(S114A) cells were plated at a density of 5 × 10 4 cells ml −1 in 24-well plates on circular glass coverslips (13-mm diameter). Cells were treated with siRNA against BRCA1 for 48 h and complemented with wild-type or BRCA1(S114) by addition of doxycycline. Cells were then treated with 20 μM olaparib for 2 h. Cells were pre-permeabilized by incubation with CSK buffer (100 mM sodium chloride, 300 mM sucrose, 3 magnesium chloride , 10 mM PIPES pH 6.8) on ice for 1 min before fixation with 4% PFA. Once fixed the cells were permeabilized for a further 5 min using 0.5% Triton X-100 in PBS before incubation with blocking solution (10% FCS in PBS for 30 min). Cells were then incubated with rabbit polyclonal RAD51 (H92) antibody in 10% FCS in PBS at room temperature overnight. The following day, cells were washed in FCS in PBS before incubation with Alexa Fluor 488 secondary antibody (1:2,000) for 2 h. Cells were then washed three times in PBS and the DNA was stained using Hoechst at a 1:20,000 concentration for 5 min. Excess of Hoechst was removing by washing with PBS and coverslips were mounted onto Snowcoat slides using Immunomount mounting medium. EdU staining. Cells that were subjected to immunofluorescence staining were also subjected to EdU staining. Cells were incubated with EdU at a final concentration of 10 μM for 2 h before fixing and staining was carried out as detailed in the Click-iT EdU Imaging Kits (Life Technologies). CldU immunostaining. Cells were plated at a density of 5 × 10 4 cells ml −1 in 24-well plates on circular glass coverslips (13-mm diameter). Cells were treated as described and incubated at 37 °C with CldU at a final concentration of 25 μM for 20 min. Cells were then fixed with 4% PFA and permeabilized for 5 min using 0.25% Triton X-100 in PBS. After permeabilization, cells were washed twice with PBS and twice with blocking solution containing 10% FCS in PBS. HCl (2 M) was added for 30 min at 37 °C and cells were incubated with 10% FCS in PBS for 1 h at room temperature. Cells were then incubated with anti-Flag (1:1,000; M2, Sigma) and rat anti-BrdU (1:500; AbD Serotec) in 10% FCS in PBS at room temperature, for 1 h. After incubation with primary antibodies, cells were washed 3 times in PBS and then incubated for 10 min in stringency buffer (0.5 M NaCl, 36 mM Tris pH 7.5-8, 0.5% Tween 20), before incubation with Alexa Fluor antibodies at a 1:500 concentration for 2 h. Cells were then washed twice with PBS and once with stringency buffer, and the DNA was stained using Hoechst at a 1:20,000 concentration for 5 min. Excess of Hoechst was removing by washing with PBS and coverslips were mounted onto Snowcoat slides using Immunomount mounting medium. PLA. Flp-In U20S cells were seeded at 4 × 10 4 cells ml −1 onto poly-l-lysine-coated coverslips and pulsed with EdU for 10 min at 37 °C for 10 min. Hydroxyurea (5 mM) was then added into the medium for 4 h at 37 °C. Likewise, cells were treated with roscovitine (25 μM) for 4 h at 37 °C. Cells were pre-extracted for 5 min on ice with pre-extraction buffer (20 mM NaCl, 3 mM MgCl 2 , 300 mM sucrose, 10 mM PIPES, 0.5% Triton X-100) and fixed in 4% PFA for 10 min before blocking in 10% BSA for 16 h. Blocking medium was removed and Click-iT reaction cocktail (PBS, 10 μM biotin azide, 10 mM sodium ascorbate, 1 mM CuSO 4 ) was added for 1 h at room temperature. The Click-iT reaction was washed and the cells were blocked in 10% BSA for 30 min. Cells were then incubated with the primary antibodies biotin (Jackson Immunoresearch) and RAD51 (Calbiochem) or BRCA1(pS114) (rabbit polyclonal) in 5% FCS in PBS for 1 h at room temperature. After incubation with primary antibodies, cells were incubated with the MINUS or PLUS PLA probes (Sigma Duolink PLA kit) for 1 h at 37 °C in a warm foil-covered box. Cells were then washed twice for 5 min with wash buffer A (Sigma Duolink PLA kit) and incubated with the Sigma Duolink ligation kit (1× ligation buffer, ligase enzyme) for 30 min at 37 °C. Cells were washed twice for 5 min with wash buffer A and incubated for 100 min at 37 °C with the Sigma Duolink amplification kit (1× amplification buffer, polymerase enzyme). Finally, the cells were washed twice for 10 min with wash buffer B (Sigma Duolink PLA kit) at room temperature, and coverslips were mounted using the Duolink mounting medium with DAPI (Sigma). For cells that were treated with CIP (NEB), fixed cells were re-permeabilized with 0.2% Triton X-100 in PBS for 5 min before incubation with 20 U CIP for 20 min at 4 °C. Cells were then blocked and assayed as described above. Microscopy. Immunofluorescence staining was imaged using the Leica DM6000B microscope using a HBO lamp with a 100-W mercury short-arc UV bulb and four filter cubes, A4, L5, N3 and Y5, which produce excitations at wavelengths 360, 488, 555 and 647 nm, respectively. Metaphase spreads. Flp-In U20S cells were treated with 5 mM hydroxyurea for 4 h and then incubated with colcemid (0.05 μg ml ) for 16 h. Cells were trypsinized and centrifuged at 1,200 r.p.m. for 5 min. The supernatant was discarded and cells were resuspended in PBS. Five millilitres of ice-cold 0.56% KCl solution was added, and cells were incubated at room temperature for 15 min before centrifuging at 1,200 r.p.m. for 5 min. The supernatant was discarded and the cell pellet was broken before fixation. Cells were then fixed in 5 ml of ice-cold methanol:glacial acetic acid (3:1). Fixation agents were removed and 10 μl of the cell suspension was dropped onto an acetic-acid-humidified slide. Slides were allowed to dry for at least 24 h and then stained with Giemsa solution (Sigma) diluted 1:20 for 20 min. Slide mounting was performed with Eukitt (Sigma). Expression and purification of wild-type and His-tagged BRCA1 1-500 -BARD1 27-327 for in vitro analysis. The expression of His-tagged wild-type BRCA1 plus wild-type BARD1, and His-tagged BRCA1(P115A) plus wild-type BARD1, was induced in Rosetta (DE3) cells by the addition of 1 mM isopropyl-β-dthiogalactopyranoside (IPTG). Proteins were produced in LB medium that contained 50 μg ml −1 kanamycin, 100 μg ml −1 of ampicillin and 30 μg ml −1 chloramphenicol at 37 °C for 5 h. For purification of the His-tagged wild-type BRCA1 plus wild-type BARD1, and His-tagged BRCA1(P115A) plus wild-type BARD1, the cells were collected and resuspended in 20 mM HEPES potassium salt pH 7.4, 50 mM imidazole, 500 mM NaCl, 1.0 mM tris(2-carboxyethyl)phosphine (TCEP), with the addition of cOmplete EDTA-free protease inhibitor cocktail tablets (Roche). Cells were lysed using an Emulsiflex-C3 homogenizer (Avestin) and broken by three passages through the chilled cell. The lysate was centrifuged at 75,000g using a JA 25.50 rotor (Beckman Coulter) and filtered through a 0.45-μm filter. The clarified lysate was applied onto a 5-ml HisTrap HP column (GE Healthcare). The column was washed extensively using the same buffer, and the protein was eluted using buffer containing 500 mM imidazole.
Fractions containing a band of the correct size were concentrated using a Vivaspin 20-ml concentrator with a 10,000 molecular mass cut-off (GE Healthcare) and gel-purified using an Akta Pure 25 (GE Healthcare LS) with a prepacked Hi-Load 10/300 Superdex 200 PG column. Expression and purification of wild-type and S114A BRCA11-300-BARD126-142 for CDK kinase assay. BRCA1 and BARD1 proteins were expressed from a pET15b-His-BRCA1 1-300 :His-BARD1 26-142 vector in BL21(DE3) bacteria (Bioline). Bacteria were grown at 37 °C until an optical density of 0.6 was reached. Protein expression was induced by addition of 0.5 mM IPTG (Bioline), and the temperature was immediately decreased to 25 °C. Bacteria were grown for a further 24 h. Bacterial pellets were collected after centrifugation at 3,000g for 10 min at 4 °C and then lysed in ice-cold lysis buffer (50 mM sodium phosphate pH 7, 300 mM sodium chloride, 5% glycerol and 10 mM β-mercaptoethanol). Lysates were sonicated for 1 min at 30% intensity and then clarified by centrifugation at 14,000g for 10 min at 4 °C. The supernatant was incubated with 0.25 ml His-Select beads (Sigma) overnight at 4 °C with rotation. The following day, the beads were washed 3 times with ice-cold wash buffer (50 mM sodium phosphate pH 7, 300 mM sodium chloride, 5% glycerol, 10 mM β-mercaptoethanol and 50 mM imidazole) before elution on ice in 50 mM sodium phosphate pH 7, 300 mM sodium chloride, 5% glycerol, 10 mM β-mercaptoethanol and 300 mM imidazole. Purified proteins were dialysed against 25 mM Tris HCl pH 7.5, 10% glycerol, 2 mM dithiothreitol (DTT) and 150 mM potassium chloride, and purity was assessed by resolution on a 15% SDS-PAGE gel. GST-PIN1 (full-length) and GST-WW purification. Bl21 Escherichia coli were transformed with the pGEX protein expression vector containing either full-length PIN1 or the WW domain of PIN1 (wild-type or W34A). Colonies were selected and then grown in 50-ml starter cultures containing ampicillin at 37 °C for 16 h at 200 r.p.m. Starter cultures were transferred to 500 ml LB containing ampicillin, and grown for 2 h at 37 °C at 200 r.p.m. Bacterial expression was induced using 0.5 mM IPTG and bacteria were left to grow for 5 h at 37 °C at 200 r.p.m.
Bacteria were pelleted by centrifuging at 12,000 r.p.m. for 10 min at 4 °C. Then the bacterial pellet was lysed in 10 ml GST lysis buffer (20 mM Tris HCl pH 8, 130 mM NaCl, 1 mM EGTA, 1.5 mM MgCl 2 , 1% Triton X-100, 10% glycerol, 1 mM DTT) with the addition of one protease inhibitor tablet (Roche). Bacteria were resuspended and left on ice for 20 min and then sonicated twice at 20% intensity for 10 s. Lysed bacteria were spun 20 min at 13,000 r.p.m. to pellet debris. The supernatant was transferred to a 50-ml falcon tube, made up to 35 ml with lysis buffer and 500 μl pre-washed glutathione sepharose 4B beads (GE Life Sciences) and rotated at 4 °C for 16 h. CDK kinase assays. A total of 50 ng of wild-type or S114A His-tagged BRCA1 1-300 -His-BARD1 26-142 was incubated with 50 ng of recombinant CDK1-cyclin A2 (Thermo Fisher Scientific; PV6280), CDK2-cyclin A (Thermo Fisher Scientific; PV3267) or CDK9-cyclin K (CDK2-cyclin A (Thermo Fisher Scientific; PV4335) in 25 mM MOPS pH 7.2, 12.5 mM β-glycerophosphate, 25 mM magnesium chloride, 5mM EGTA, 2 mM EDTA, 0.5 mM DTT and 50 ng μl −1 BSA. The kinase reaction was started by addition of 10 mM ATP and samples were incubated at 30 °C for 30 min. The reaction was stopped by addition of 4× SDS-PAGE loading buffer and incubated at 95 °C for 5 min. A sample of 5 μl of the total reaction was run on 14% SDS-PAGE gel before transfer to an Immobilon-P membrane (MERCK Millipore) and western blotting for phosphorylated Ser114 (3C10G8) or BRCA1 (MS110).
RAD51 in vitro binding assays with BRCA1-BARD1 N-terminal fragments.
A total of 0.5 μl of human recombinant RAD51 (ab63808; Abcam) was incubated with 40 μl of a 50% slurry of His-tagged wild-type BRCA1 plus wild-type BARD1, or His-tagged BRCA1(P115A) plus wild-type BARD1, immobilized in Ni 2+ resin together with 500 μl of RAD51 binding buffer (25 mM Tris HCl pH 7.5, 10% glycerol, 0.5 mM EDTA, 0.05% IGEPAL CA-630, 1 mM 2-mercaptoethanol, 150 mM KCl, 50 mM imidazole) for 30 min at 4 °C in rotation. After incubation the resin was washed 3 times with the RAD51 binding buffer before eluting in 40 μl 4× SDS loading buffer at 95 °C for 5 min. The SDS elute was then analysed by western blotting and staining with Coomassie blue. In vitro PIN1 incubations with BRCA1-BARD1 and RAD51. Using recombinant BRCA1 preparations, 50 μl of His-tagged wild-type BRCA1 1-500 -BARD1 27-327 or the phosphomimetic S114D was incubated at 37 °C for 1 h with 2 μl of fulllength GST-PIN1 or BSA in 10 mM ATP in 50 mM Tris pH 7.4, 500 mM NaCl, 1 mM DTT, 500 mM imidazole, 5% glycerol and 0.01% IGEPAL CA-630. This was then incubated for a further 2 h at 4 °C with 0.5 μl human recombinant RAD51 (ab63808; Abcam) in 500 μl of RAD51 binding buffer (25 mM Tris HCl pH 7.5, 10% glycerol, 0.5 mM EDTA, 0.05% IGEPAL CA-630, 1 mM 2-mercaptoethanol, 150 mM KCl, 50 mM imidazole) and 30 μl of His-Select beads (Sigma). Beads were then washed three times in RAD51 binding buffer before eluting in 60 μl 4× SDS loading buffer at 95 °C for 5 min.
Alternatively, 0.3 μg of wild-type His-tagged BRCA1 1-300 and His-tagged BARD1 26-142 was incubated with or without 100 ng of recombinant CDK1-cyclin A2 (Thermo Fisher Scientific; PV6280), in 150 μl of 25 mM MOPS pH 7.2, 12.5 mM β-glycerophosphate, 25 mM magnesium chloride, 5 mM EGTA, 2 mM EDTA, 0.5 mM DTT and 50 ng μl −1 BSA with 20 mM ATP at 37 °C for 2 h. Subsequently, 50 μl BSA, or wild-type His-tagged BRCA1 1-300 and His-tagged BARD1 26-142 or CDK1-phosphorylated His-tagged BRCA1 1-300 and His-tagged BARD1 26-142 was incubated with 2 μl of full-length GST-PIN1 or BSA in 10 mM ATP in 50 mM Tris pH 7.4, 500 mM NaCl, 1 mM DTT, 500 mM imidazole, 5% glycerol and 0.01% IGEPAL CA-630 for 5 min at room temperature. This was then incubated for a further 2 h at 4 °C with 0.5 μl human recombinant RAD51 (ab63808; Abcam) in 500 μl of RAD51 binding buffer (25 mM Tris HCl pH 7.5, 10% glycerol, 0.5 mM EDTA, 0.05% IGEPAL CA-630, 1 mM 2-mercaptoethanol, 150 mM KCl, 50 mM imidazole) and 30 μl of His-Select beads (Sigma). Beads were then washed 3 times in ice-cold PBS before eluting in 60 μl 4× SDS loading buffer at 95 °C for 5 min. Cloning and purification of full-length BRCA1-BARD1. BRCA1 and BARD1 genes were synthesized with codons optimised for insect cell expression. The BRCA1 gene was then fused to an N-terminal His tag and a C-terminal Strep tag. Mutagenesis was carried out by PCR using CloneAmp HiFi PCR premix (Takara) and the primers indicated in Supplementary Table 1. Mutagenesis was confirmed by Sanger sequencing (Eurofins). Genes were cloned into the MultiBac system for expression in insect cells 51 . BRCA1-BARD1 complexes were expressed in Sf9 insect cells for 60 h postinfection in Insect-XPRESS Protein-free Insect Cell Medium with l-glutamine (Lonza). Cells were collected and resuspended in lysis buffer (50 mM NaPO 4 pH 8.0, 150 mM KCl, 0.5% NP-40, 0.01% Tween 20, 10% glycerol, 0.5 mM TCEP), BaseMuncher (Expedeon), 1 mM benzamidine and protease inhibitors (AEBSF (1 mM), aprotinin (800 nM), bestatin (50 μM), E-64 (15 μM), leupeptin (20 μM), pepstatin (10 μM)). The lysate was clarified by centrifugation at 36,000g for 1 h at 4 °C, passed through a 0.45-μm syringe filter and loaded onto a 5-ml StrepTrap HP column (GE Healthcare). The column was washed with lysis buffer followed by buffer A (50 mM NaPO 4 pH 8.0, 150 mM KCl, 0.01% Tween 20, 10% glycerol, 0.5 mM TCEP) and then buffer B (50 mM NaPO 4 pH 8.0, 50 mM KCl, 0.01% Tween 20, 10% glycerol, 0.5 mM TCEP). The protein was eluted onto a 1-ml HiTrap SP HP column (GE Healthcare) using elution buffer (wash buffer B supplemented with 0.4 mg ml −1 d-desthiobiotin (Sigma)). The SP column was washed with buffer C (25 mM HEPES pH 7.4, 0.01% Tween 20, 10% glycerol, 0.5 mM TCEP) supplemented with 50 mM KCl. The protein was then eluted using a 0.05-1 M KCl gradient in buffer C. Peak fractions were pooled and concentrated with an Amicon 100-kDa molecular weight cut-off centrifugal filter unit (Sigma). The concentrated protein was loaded onto a Superose 6 Increase 10/300 column (GE Healthcare) and gel-filtrated in buffer C supplemented with 150 mM KCl. Peak fractions were pooled, flash-frozen in liquid nitrogen and stored at −80 °C. Purification of RAD51 for binding assays with full-length BRCA1-BARD1. RAD51 was purified according to a previously described protocol 52 . In brief, RAD51 was expressed from Acella DE3 E. coli induced with IPTG for 4 h at 37 °C. The pellet was resuspended in lysis buffer (100 mM Tris-OAc pH 7.5, 2 mM EDTA, 10% glycerol, 1 mM DTT, protease inhibitor cocktail, lysozyme 0.5 mg ml −1 , 0.1% Triton X-100). The resuspended cells were sonicated and the lysate clarified by centrifugation at 18,000 r.p.m. at 4 °C for 1 h 20 min. The supernatant was dialysed in spermidine acetate buffer (20 mM Tris-OAc pH 7.5, 7 mM spermidine, 5% glycerol, 0.1 mM DTT). RAD51 was selectively resuspended in buffers containing an increasing concentration of NaCl. The fractions were then purified with a HiTrap Q HP column (GE Healthcare). RAD51 in vitro binding assays with full-length BRCA1-BARD1. BRCA1-BARD1 (0.5 μM) was pre-incubated with RAD51 (5 μM, a gift from Y. Sun) for 30 min at 4 °C. A total of 80 μl of a 50% slurry of streptactin sepharose high performance resin (GE Healthcare) in binding buffer (25 mM Tris pH 7.5, 90 mM KCl, 1 mM TCEP, 0.2% Tween 20), with 5 mM MgCl 2 and 3 mM ATP, was added and incubated for a further 30 min at 4 °C. The resin was washed with 2 ml binding buffer and eluted with 40 μl 4× NuPAGE LDS Sample Buffer (Thermo Fisher Scientific). Samples were run on SDS-PAGE and stained with Coomassie blue (Expedeon). Proteolytic digestion with trypsin. Full-length BRCA1-BARD1 (0.1 mg ml −1 ) was subjected to proteolytic digestion with 0.01 ng μl −1 trypsin (Sigma) in 25 mM Tris HCl pH 7.5, 90 mM KCl, 1 mM TCEP and 0.2% Tween 20. Samples were incubated at room temperature and 20-μl samples were collected at time points 0, 2, 5, 10, 15, 20, 30 and 60 min and quenched with 5 μl 4× NuPAGE LDS Sample Buffer (Thermo Fisher Scientific). Samples were boiled at 100 °C for 5 min and 20 μl was loaded onto an SDS-PAGE gel. Gels were stained with Coomassie blue (Expedeon) and band intensities of full-length BRCA1 and BARD1 were measured using ImageJ software 53 . The rate constant of proteolysis (k p ) was determined by nonlinear fitting to an exponential one-phase decay curve in GraphPad Prism v.8.0.2 software. Densitometry. All densitometry was calculated using ImageJ 53 to quantify western blot and Coomassie-stained band intensities. For GST-WW pull-downs, quantification measured the fold change in BRCA1 levels observed in the pull-downs, normalized to the amount of BRCA1 in the corresponding inputs. All quantification is from at least three independent experiments.
For the densitometry to calculate the levels of RAD51 in the Flag immunoprecipitation (Extended Data Fig. 5e, f) , we calculated the relative amounts of RAD51, BRCA1 and BARD1 in the Flag immunoprecipitation from HEK293 FlpIn cells using densitometry performed with ImageJ
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. The amount of RAD51 enrichment was then calculated by normalizing RAD51 to the combined levels of BRCA1 and BARD1 for each immunoprecipitation. To calculate the percentage of intact protein in the trypsin proteolytic digestions, the amount of full-length protein was normalized to that at 0 min. DR-GFP. U2OS-DR3-GFP (gene conversion reporter cell lines) were a gift from J. Stark (City of Hope, Duarte). U20S reporter cell lines were simultaneously co-transfected with siRNA, using Dharmafect1 (Dharmacon), and DNA (RFP, or constructs that express RFP-Flag-tagged BARD1 and I-Sce1 endonuclease), using FuGene6 (Promega). After 16 h, the medium was replaced and cells were grown for a further 48 h before fixation in 2% PFA. RFP and GFP double-positive cells were scored by fluorescence-activated cell sorting (FACS) analysis using a CyAn flow cytometer, with a minimum of 10,000 cells counted. Data were analysed using Summit 6.2 software. Each individual experiment contained three technical repeats and was normalized to siRNA controls or to wild-type-complemented cells. Graphs shown are combined data from six independent experiments and error bars show standard error. The FACS gating strategy is shown in Supplementary Fig. 1 . Statistics and reproducibility. All statistical tests used a two-sided unpaired t-test and the exact P-values are given in each case. NS, not significant. All experiments were repeated at least once and the number of biological replicates (n) is reported for each experiment. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
All datasets that were generated during the current study are provided as online source data associated with this paper. The custom mouse monoclonal (3C10G8) and rabbit polyclonal antibodies that were raised against BRCA1(pS114) are available on request to the corresponding authors subject to completion of a standard MTA. Table summarizing the survival and replication fork stability responses to DNA-damaging agents by the variants of BRCA1-BARD1 that were used in this study. b, Model to illustrate CDK1 or CDK2 (grey) phosphorylation at Ser114 (red) and subsequent PIN1 (purple) isomerization events on BRCA1 (green) and BARD1 (orange). BRCA1 isomerization enhances the ability of BARD1 to associate with RAD51 (brown) and thereby promotes replication fork protection.
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